Premium
Guanabenz effects on blood pressure and noninvasive parameters of cardiac performance in patients with hypertension
Author(s) -
Shah Rajnikant S.,
Walker Barry R.,
Vanov Svetislav K.,
Helfant Richard H.
Publication year - 1976
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1976196732
Subject(s) - guanabenz , medicine , blood pressure , anesthesia , placebo , cardiology , sedation , sympatholytic , sympathetic nervous system , pharmacology , agonist , receptor , alternative medicine , pathology
Guanabenz (2,6 dichlorobenzylidene amino guanidine acetate) is a new antihypertensive whose mechanism of action appears to involve both central alpha adrenergic stimulation leading to suppression of sympathetic nervous system activity from bulbar vasoconstriction centers as welt as peripheral adrenergic neuron blockade. In this study, the drug was shown to produce a statisticalty and clinically significant decrease in blood pressure during a 4‐wk placebo‐controlted double‐blind study. For three additional months continued efficacy and safety were shown under open conditions in 17 hypertensive patients. Mild sedation occurred, but there were no postural hypotension, tachycardia, evidence of sodium retention, gastrointestinal disturbances, or electrocardiographic (ECG) abnormalities. Noninvasive parameters of cardiac performance in JO patients after single doses of guanabenz showed no significant changes. Although the numbers of patients were relatively small, the data suggest that this new drug may be a useful antihypertensive agent that warrants further investigation.”Guanabenz (2,6 dichlorobenzylidene amino guanidine acetate) is a new antihypertensive whose mechanism of action appears to involve both central alpha adrenergic stimulation leading to suppression of sympathetic nervous system activity from bulbar vasoconstriction centers as welt as peripheral adrenergic neuron blockade. In this study, the drug was shown to produce a statisticalty and clinically significant decrease in blood pressure during a 4‐wk placebo‐controlted double‐blind study. For three additional months continued efficacy and safety were shown under open conditions in 17 hypertensive patients. Mild sedation occurred, but there were no postural hypotension, tachycardia, evidence of sodium retention, gastrointestinal disturbances, or electrocardiographic (ECG) abnormalities. Noninvasive parameters of cardiac performance in JO patients after single doses of guanabenz showed no significant changes. Although the numbers of patients were relatively small, the data suggest that this new drug may be a useful antihypertensive agent that warrants further investigation.